CheckMate 227: Nivolumab plus Ipilimumab vs Chemotherapy as 1L Treatment for Advanced NSCLC With High Tumor Mutational Burden

被引：0
|
作者：
Mathias, C. [1 ]
Reck, M. [2 ]
Hellmann, M. [3 ]
Ramalingam, S. [4 ]
Brahmer, J. [5 ]
O'Byrne, K. [6 ]
Bhagavatheeswaran, P. [7 ]
Nathan, F. [7 ]
Borghaei, H. [8 ]
Paz-Ares, L. [9 ,10 ]
机构：
[1] Nucleo Oncol Bahia, Salvador, BA, Brazil
[2] German Ctr Lung Res DZL, Lung Clin Grosshansdorf, ARCN, Grosshansdorf, Germany
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[6] Princess Alexandra Hosp Brisbane, Brisbane, Qld, Australia
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA
[9] Univ Complutense, CNIO, Hosp Univ Doce Octubre, Madrid, Spain
[10] CiberOnc, Madrid, Spain
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 09期
关键词：
tumor mutational burden; patient-reported outcomes; nivolumab; NSCLC;
D O I：
10.1016/j.jtho.2018.07.021
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS2
引用
收藏
页码：S152 / S153
页数：2
相关论文
共 50 条
  • [1] CheckMate 227: Patient-Reported Outcomes of First-Line Nivolumab plus Ipilimumab in High Tumor Mutational Burden Advanced NSCLC
    Brahmer, J.
    Schenker, M.
    Lee, K. H.
    Provencio, M.
    Nishio, M.
    Lesniewski-Kmak, K.
    Sangha, R.
    Ahmed, S.
    Raimbourg, J.
    Feeney, K.
    Corre, R.
    Franke, F.
    Richardet, E.
    Penrod, J.
    Yuan, Y.
    Nathan, F.
    Bhagavatheeswaran, P.
    De Rosa, M.
    Taylor, F.
    Lawrance, R.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S332 - S332
  • [2] CheckMate 227: Nivolumab (Nivo) plus Ipilimumab (Ipi) vs platinum-doublet chemotherapy (Chemo) as first-line treatment for advanced non-small cell lung cancer (NSCLC) with high Tumor Mutational Burden (TMB)
    Reck, M.
    Hellmann, M. D.
    Paz-Ares Rodriguez, L.
    Ramalingam, S. S.
    Brahmer, J.
    O'Byrne, K. J.
    Bhagavatheeswaran, P.
    Nathan, F.
    Borghaei, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 268 - 269
  • [3] Six-year Survival and HRQoL Outcomes with 1L Nivolumab plus Ipilimumab in Patients with Metastatic NSCLC from CheckMate227
    Ramalingam, S. S.
    Ciuleanu, T. -E.
    Bernabe Caro, R.
    Nishio, M.
    Mizutani, H.
    Lee, J. -S.
    Audigier-Valette, C.
    Sangha, R.
    Urban, L.
    Burgers, J. A.
    Pluzanski, A.
    Lee, K. H.
    Zurawski, B.
    Schenker, M.
    Peters, S.
    Paz-Ares, L. G.
    Borghaei, H.
    O'Byrne, K. J.
    Brahmer, J. R.
    Gupta, R. G.
    Bushong, J.
    Li, L.
    Yuan, Y.
    Blum, S. I.
    Reck, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S76 - S77
  • [4] Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227
    Schumann, C.
    Paz-Ares, L.
    Ciuleanu, T. -E
    Lee, J. -S
    Urban, L.
    Caro, Bernabe R.
    Park, K.
    Sakai, H.
    Ohe, Y.
    Nishio, M.
    Pluzanski, A.
    Ramalingam, S. S.
    Brahmer, J. R.
    Borghaei, H.
    O'Byrne, K. J.
    Hellmann, M. D.
    Memaj, A.
    Bushong, J.
    Tran, P.
    Reck, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 173 - 173
  • [5] Survival of responders to nivolumab (NIVO) plus ipilimumab (IPI) as first-line treatment for advanced NSCLC in CheckMate 227, part 1
    Brahmer, J. R.
    Ciuleanu, T-E.
    Schenker, M.
    Audigier-Valette, C.
    Zurawski, B.
    Linardou, H.
    Kim, S-W.
    Otterson, G. A.
    Salman, P.
    De La Mora Jimenez, E.
    Lesniewski-Kmak, K.
    Ahmed, S.
    Albert, I.
    Barlesi, F.
    Feeney, K.
    Frickhofen, N.
    Li, A.
    Sun, P.
    Hellmann, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S1444 - S1445
  • [6] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
    Hellmann, M. D.
    Ciuleanu, T. -E.
    Pluzanski, A.
    Lee, J. S.
    Otterson, G. A.
    Audigier-Valette, C.
    Minenza, E.
    Linardou, H.
    Burgers, S.
    Salman, P.
    Borghaei, H.
    Ramalingam, S. S.
    Brahmer, J.
    Reck, M.
    O'Byrne, K. J.
    Geese, W. J.
    Green, G.
    Chang, H.
    Szustakowski, J.
    Bhagavatheeswaran, P.
    Healey, D.
    Fu, Y.
    Nathan, F.
    Paz-Ares, L.
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22): : 2093 - 2104
  • [7] Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab plus Ipilimumab in mNSCLC in CheckMate 227
    Reck, M.
    Worthy, G.
    Yuan, Y.
    Penrod, J. R.
    Lawrance, R.
    Taylor, F.
    Blum, S. I.
    Moisei, A.
    Lee, A.
    Ciuleanu, T. -E.
    Pluzanski, A.
    Lee, J. -S.
    Ramalingam, S.
    Borghaei, H.
    O'Byrne, K.
    Paz-Ares, L.
    Li, L.
    Gupta, R. G.
    Bushong, J.
    Brahmer, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S320 - S321
  • [8] First-line nivolumab plus ipilimumab in advanced NSCLC: CheckMate 227 subpopulation analyses in Asian patients
    O'Byrne, K. J.
    Lee, K. H.
    Kim, S-W
    Park, K.
    Nishio, M.
    Sakai, H.
    Ohe, Y.
    Fukuhara, T.
    Kang, J-H
    Daga, H.
    Yu, C-J
    Hotta, K.
    Tanaka, H.
    Takeda, M.
    Yokoyama, T.
    Nathan, F. E.
    Lee, J-S
    ESMO OPEN, 2022, 7 (01)
  • [9] CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC
    Paz-Ares, L.
    Urban, L.
    Audigier-Valette, C.
    Grossi, F.
    Jao, K.
    Aucoin, J.
    Linardou, H.
    Poddubskaya, E. Vladimirovna
    Fischer, J.
    Fontecedro, A. Curioni
    Groen, H.
    Vermaelen, K.
    Bourhaba, M.
    Kowalski, D.
    Pillai, R.
    Spigel, D.
    Ahmed, S.
    Hu, W.
    Vickery, D.
    Fiore, J.
    Ready, N.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S493 - S493
  • [10] Nivolumab plus chemotherapy vs chemotherapy in EGFR-mutated NSCLC after 1L or 2L EGFR-TKIs (CheckMate 722)
    Park, Keunchil
    Yang, James Chih-Hsin
    Girard, Nicolas
    Mok, Tony
    Gainor, Justin
    Nakagawa, Kazuhiko
    Wu, Yi-Long
    Xu, Wanning
    Yang, Rong
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2019, 30
12345